U.S. Markets closed
  • S&P 500

    -54.85 (-1.51%)
  • Dow 30

    -500.09 (-1.71%)
  • Nasdaq

    -161.88 (-1.51%)
  • Russell 2000

    -10.21 (-0.61%)
  • Crude Oil

    -1.49 (-1.83%)
  • Gold

    -0.30 (-0.02%)
  • Silver

    +0.30 (+1.62%)

    -0.0018 (-0.1862%)
  • 10-Yr Bond

    +0.0570 (+1.52%)
  • Vix

    -0.22 (-0.69%)

    +0.0043 (+0.3841%)

    +0.2770 (+0.1918%)

    -75.04 (-0.39%)
  • CMC Crypto 200

    +0.06 (+0.01%)
  • FTSE 100

    +12.22 (+0.18%)
  • Nikkei 225

    -484.89 (-1.84%)

Gritstone (GRTS) Inks Deal With CEPI for Coronavirus Vaccine

·2 min read

Gritstone bio, Inc. GRTS announced that it has entered into a funding agreement with the Coalition for Epidemic Preparedness Innovations (“CEPI”) for up to $20.6 million to advance the development of its COVID-19 vaccine program, CORAL, with an initial focus in South Africa.

Shares of Gritstone were up 8.5% on Tuesday following announcement of the news. In fact, the stock has skyrocketed 120.3% so far this year against the industry’s decrease of 1%.

Zacks Investment Research
Zacks Investment Research

Image Source: Zacks Investment Research

Per the agreement, CEPI will providing funding for the multi-arm phase I study which will evaluate Gritstone’s second-generation self-amplifying mRNA (“SAM”) vaccines against SARS-CoV-2, the virus that causes COVID-19 in naïve, convalescent as well as HIV+ patients. The CEPI funding will also support pre-clinical studies, scale-up, and formulation development for a stabler drug product. The study is expected to begin by the end of this year.

Per the company, the SAM vaccine has the potential to provide both prolonged protection and potency against spike mutants and durable immunity against variants of COVID-19. With the CORAL phase I program, Gritstone is looking to establish optimal dosing and antigenic content in young individuals, the elderly, the previously vaccinated and the immuno-compromised population, including people living with HIV.

Through this agreement with CEPI, Gritstone has agreed that if the vaccine candidate is proven to be safe and effective, it will be made available to the COVAX Facility for procurement and allocation to several countries across the world.

We note that several companies have already come up with their respective vaccines for fighting the COVID-19 virus.

Pfizer/BioNTech’s BNTX mRNA-based COVID-19 vaccine, BNT162b2, is approved for emergency/temporary/conditional use in several countries. Another mRNA-based COVID-19 vaccine candidate, mRNA-1273, developed by Moderna, Inc. MRNA, has also been approved for emergency/temporary use in various countries. J&J’s single-shot COVID-19 vaccine is also available in the United States for emergency use.

AstraZeneca’s AZN adenovirus-based coronavirus vaccine (called Vaxzevria in EU) is approved for emergency use in several countries, including India. The vaccine is not available in the United States.

Zacks Rank

Gritstone currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

AstraZeneca PLC (AZN) : Free Stock Analysis Report

Moderna, Inc. (MRNA) : Free Stock Analysis Report

Gritstone bio Inc. (GRTS) : Free Stock Analysis Report

BioNTech SE Sponsored ADR (BNTX) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research